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Abstract
Background: There is a paucity of studies on inflammatory markers in elderly psychiatric patients. Hence, our study
was undertaken to investigate cytokines as biomarkers in diagnostically unselected elderly patients admitted to a
psychiatric hospital.
Methods: Demographic data, clinical data and blood samples, including 27 cytokines, were collected from 98
patients above 60 years, consecutively admitted to a psychiatric hospital in Tromsø, Norway (69°N).
Results: The most common diagnosis was Recurrent depressive disorder (26.5%), the second most common was
dementia in Alzheimer’s disease (20.4%). The most frequent somatic disease was cardiovascular disease (28%).
No statistical association (p < 0.01) was found between cytokines and gender, age, BMI, anti-inflammatory drugs,
psychotropic drugs, reason for admittance, smoking, vitamin supplements, alcohol consumption, length of stay,
somatic disease (present/not-present) or psychiatric diagnoses. However, when allocating patients to two groups,
depression and no depression, we found higher levels of 10 cytokines in the no depression group (FDR-p < 0.0044).
Possibly, this could in part be explained by the higher prevalence of cardiovascular disease (CVD) and dementia in
the no depression group, as these factors were significant predictors of patients being categorized as not
depressed in a logistic regression. In addition, other unknown factors might have contributed to the association
between no depression and elevated cytokines. On the other hand, the high level of psychiatric and somatic
comorbidity in the study population may have led to increased levels of cytokines in general, possibly diluting the
potential effect of other factors, depression included, on the cytokine levels.
The size of the study, and particularly the size of the subgroups, represents a limitation of the study, as do the
general heterogeneity and the lack of a control group.
Conclusions: There was no significant difference in cytokine levels between various psychiatric diagnoses in
hospitalized elderly psychiatric patients. This indicates that previous findings of correlations between cytokines and
various psychiatric disorders in highly selected adult cases might not be applicable to elderly psychiatric inpatients.
Further immunological studies are needed on gerontopsychiatric patients in general and gerontopsychiatric
patients with specific disorders, preferably with patients that are physically healthy.
Trial registration: Retrospectively registered in the ISRCTN registry study, with study ID ISRCTN71047363.
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Background
Several studies have demonstrated an association be-
tween psychiatric disorders and biomarkers of inflamma-
tion, particularly cytokines. Primarily, these studies have
focused on specific disorders and selected sets of cyto-
kines. Depression and schizophrenia seem to dominate
this research, both disorders repeatedly demonstrating
elevated levels of pro-inflammatory cytokines such as
IL-1β, IL-2, IL-6, and TNF [1–3]. Though some of these
studies include elderly patients [4–6], most studies have
been conducted on younger adults. Thus, there is a pau-
city of studies on elderly psychiatric patients and par-
ticularly elderly psychiatric in-patients. Besides the fact
that populations are ageing in most countries [7], the
elderly are of particular interest because they are more
likely to represent biological diversity due to age-related
neuroimmunological changes [8] and higher frequencies
of comorbid conditions. Consequently, findings of cyto-
kine changes in younger adults do not readily translate
to elderly psychiatric patients. Hence, our study was
undertaken to investigate cytokines as biomarkers in




The population has been described in a previous publi-
cation [9]. Demographic data, clinical data and blood
samples were collected from 98 patients, 60 years and
older, consecutively admitted to a psychiatric hospital in
Tromsø, Norway (69°N). The catchment area of the hos-
pital was approximately 250,000 citizens. Exclusion cri-
teria comprised inability to communicate and cooperate,
e.g. due to a severe psychiatric condition like severe de-
mentia or confusion/delirium, or a medical condition
likely to significantly affect the blood/plasma analysis
like severe dehydration or ongoing infection. The rea-
sons for referral included a variety of psychiatric condi-
tions, spanning from anxiety to psychosis, with
depression (42%) and dementia (26%) being the most
common. In terms of gender, age and diagnostic distri-
bution, the study population was quite similar to the
general population of patients admitted to gerontopsy-
chiatric units in Norway [10], the possible exception
being a lower proportion of dementia. However, the
Norwegian national data included patients with severe
dementia, whereas these patients were excluded from
our study.
Clinical assessment
The following instruments were applied to assess the psy-
chiatric and cognitive status of the participants (N = num-
ber of patients): the MINI International Neuropsychiatric
Interview, N = 43 [11], the Montgomery and Aasberg
Depression Rating Scale, N = 76 [12], the Cornell Scale for
Depression in Dementia, N = 22 [13], the Mini-Mental
State Examination, N = 92 [14] and the Clockdrawing
Test, N = 90 [15]. In addition, clinical interviews and re-
views of medical records were undertaken by experienced
clinicians in assessment and diagnostics, according to
ICD-10 research criteria. Interview of next of kin was also
undertaken when appropriate.
Blood samples
During the first 3 days of admittance, morning blood
samples (before 10 AM) were obtained for a range of
analyses, e.g. electrolytes, liver enzymes, blood cells and
thyroid hormones. In addition, plasma samples from
EDTA-tubes were successively and rapidly frozen to −
70 °C, until analysed for cytokines in one batch. The
analyses were performed by multiplex technology on a
Multiplex Analyser with a predefined kit, according to
the instructions of the manufacturer (Bio-Plex Human
Cytokine 27-Plex Panel; Bio-Rad Laboratories Inc.,
Hercules, CA, USA). The assay was set up to detect the
following interleukins, chemokines and growth factors:
IL-1β, IL-1 receptor antagonist (IL1-ra), IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15,
IL-17, eotaxin, basic fibroblast growth factor (bFGF),
granulocyte-colony stimulating factor (G-CSF), granulo-
cyte macrophage colony stimulating factor (GM-CSF),
interferon (IFN)-γ, interferon-inducible protein (IP-10),
monocyte chemotactic protein (MCP-1), macrophage in-
flammatory protein (MIP-1α, MIP-1β), platelet derived
growth factor-BB (PDGF-BB), regulated upon activation
T cell expressed and secreted (RANTES), tumor necrosis
factor (TNF), and vascular endothelial growth factor
(VEGF).
GM-CSF and IL-15 had a high frequency of
non-detectable levels, i.e. below the lower detection
limit, and were therefore excluded in the statistical ana-
lyses. Another eight cytokines had a small number of pa-
tients with cytokine levels below the lower detection
limit (number of patients with non-detectable levels):
IL-2 (4), IL-10 (11), IL-13 (1), IL-17 (4), bFGF (2),
G-CSF (2), PDGF-BB (2), and VEGF (4). Data for these
patients were imputed using SPSS, see Statistical ana-
lyses section.
Statistical analyses
Most of the data were not strictly normally distributed,
as demonstrated by the Kolmogorov-Smirnov test, and
several groups had unequal variances. Thus, nonpara-
metric tests were applied. The Spearman rank correl-
ation coefficient and Kendall Tau coefficient were used
to analyse differences between the rankings of two vari-
ables. The Mann-Whitney U or the Kruskal-Wallis tests
were applied when comparing ranks of two or several
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subgroups, subsequently. Goodness of fit was assessed
by binary logistic regression. To examine whether the
raised cytokine levels and the other variables could predict
depression, we performed logistic regression analyses with
depression/no depression as dependent variable. Patients
were allocated to the depression group if they had been
given depression as a primary or secondary diagnosis, or
the no depression group if they had not been given a de-
pression analysis.
Due to multiple statistical analyses, 0.01 was selected as
significance level. In addition, false detection rate adjusted
p-value (FDR-p) was calculated and applied to all analyses
related to the cytokines. IBM Statistical Package for the
Social Sciences, Version 23 (SPSS Inc., Chicago, Illinois,
USA) software was used in the statistical analysis.
A small group of patients had no or very low levels of
certain cytokines (which is a common finding for most
cytokines in healthy adults), but the actual value could
not be computed by the instrumentation; they are
so-called non-detects (NDs). Accordingly, data from the
NDs could hold valuable information, and in order to in-
clude them in the statistical analyses, we did single im-
putations, i.e. the NDs were substituted with a random
value between zero and the lower detection limit, with a
uniform distribution, using the random number gener-
ator of SPSS [16].
Results
Population characteristics
Population characteristics are presented in Table 1.
Diagnoses
The main diagnostic groups are presented in Table 2.
The most common diagnosis was Recurrent depressive
disorder (26.5%), the second most common was demen-
tia in Alzheimer’s disease (20.4%). Considering depres-
sion as a separate clinical entity, depending on whether
the patients had been given depression as a primary or
secondary diagnosis or not, the majority of patients
could be allotted to the depression group, see Table 2.
Selected features of the groups depression and no de-
pression are presented in Table 3.
Distribution and correlation analysis
The cytokine values of the patients are presented in
Table 4. In this group of diagnostically unselected elderly
in-patients, no statistical correlation or unequal distribu-
tion was found between cytokines and gender, age, BMI,
anti-inflammatory drugs, psychotropic drugs, reason for
admittance, smoking, vitamin supplements, alcohol con-
sumption, length of stay, somatic disease (present/not--
present) or psychiatric diagnoses, dementia included.
However, a correlation (FDR-p < 0.0044) was found
between no depression (N = 39) and raised levels of sev-
eral cytokines, see Table 5.
While none of the raised cytokine levels predicted de-
pression in a logistic regression model, cardiovascular dis-
ease (CVD) and dementia were predictors of patients
being categorized as not depressed/no depression (Table 6).
However, none of the cytokines came out as predictive in
logistic regression models with CVD/no CVD, or demen-
tia/no dementia, as dependent variables.
Looking at distributional data, CVD and dementia
were more prevalent in the no depression group, com-
pared to the depression group, 46.2% versus 15.3%, and
51.3% versus 22.0%, respectively.
Table 1 In-patients’ characteristics
Characteristics
Age, median/SD (years) 76/7.3
80 years and older (%) 39.8
Women (%) 61.2
Men (%) 38.8
Length of stay, median/SD (days) 34/25
Living alone (%) 53
Previous hospitalization (%) a 49
Two or more previous hospitalizations (%) a 38
No known somatic disease (%) 21
Cardiovascular disease (%) 28
Pulmonary disease (%) 10
Thyroid disease (%) 10
Previous stroke (%) 10
Rheumatic disease (%) 3.5
Other somatic diseases (%) 17.5
Potentially anti-inflammatory drug (%) b 55.1
Daily smokers (%) 29.6
BMI, median/SD (kilos) 24/5.3
a Psychiatric hospitalization
b The most common drug in this category is acetylsalicylic acid in low dose as
prevention of cardiovascular events (N = 30/68.2%)
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Discussion
To our knowledge, this is the first study to explore cyto-
kine levels in diagnostically unselected elderly psychi-
atric in-patients. Using an immunoassay method, we
analysed 27 plasma cytokines in 98 patients, 60 years
and older, admitted to a gerontopsychiatric unit.
The results demonstrated that cytokine levels did not
correlate with variables such as age, gender, psychiatric
diagnoses, somatic disease (present/not present), and
the use of anti-inflammatory and psychotropic drugs.
Considering each of these factors separately, this does
not seem to match previous findings, as prior studies
have shown positive associations between for instance
Alzheimer’s disease and increased levels of several cyto-
kines [17], and between aging and increased levels of
IL-6 and TNF-α [18]. Then again, our heterogeneous
study population differs substantially from most of the
diagnostically uniform populations previously studied.
The high frequency of somatic and psychiatric comor-
bidity in the study population may have contributed to
the increased levels of cytokines in general, masking
possible correlations between any single factor and
changes in levels of cytokines. On the other hand, there
is a possibility that altered immune activity in psychiatric
patients is a general phenomenon, not restricted to spe-
cific diagnoses. Such a hypothesis can be bolstered by
the fact that research has shown raised levels of inflam-
matory markers in several psychiatric disorders, ranging
from schizophrenia to anxiety disorders [19, 20].
Contrary to some prior studies, we did not find any cor-
relation between cytokines and depression. Given the fact
the majority of our depressed patients were diagnosed
with recurrent depressive disorder, it could be
Table 3 Selected features of depressed and non-depressed
patients
Comorbidities/features Depression (%) No depression (%)
Somatic disease (any) 76.3 82.1
Cardiovascular disease 15.3 46.2
Dementia 22.0 51.3
Antidepressants 74.6 25.6
Table 4 Serum levels of cytokines (pg/ml) in elderly psychiatric in-patients
Cytokine Median SD* Minimum Maximum P 25** P 75***
IL-1b 3.00 4.65 0.53 38.00 1.58 5.00
IL-1ra 158.00 769.64 31.00 7396.00 84.00 268.75
IL-2 9.00 17.97 0.01 147.00 3.00 16.00
IL-4 3.00 2.55 1.00 13.00 2.00 4.00
IL-5 5.00 5.65 0.73 28.00 3.00 9.00
IL-6 11.00 15.39 3.00 119.00 7.00 18.75
IL-7 21.00 22.83 0.25 104.00 11.00 36.00
IL-8 13.00 9.35 3.00 47.00 8.00 19.00
IL-9 18.00 47.03 3.00 441.00 11.00 28.00
IL-10 8.50 16.92 0.01 102.00 2.00 16.00
IL-12 27.00 51.60 0.05 381.00 11.00 46.75
IL-13 7.00 15.51 0.50 96.00 4.00 14.00
IL-17 42.50 66.57 0.35 371.00 15.25 88.25
Eotaxin 93.00 257.20 28.00 2286.00 65.50 157.75
bFGF 46.00 48.58 1.16 259.00 21.00 79.75
G-CSF 52.00 52.92 1.53 316.00 29.25 82.75
INF-g 184.00 217.26 20.00 1179.00 94.75 280.75
IP-10 1015.50 744.58 216.00 5075.00 762.25 1338.00
MCP-1 19.00 16.04 4.00 128.00 13.25 26.00
MIP-1a 10.00 9.82 2.00 58.00 6.00 15.00
MIP-1b 44.00 24.77 17.00 198.00 34.00 56.00
PDGF-BB 137.50 325.59 1.03 1651.00 34.25 308.00
RANTES 6642.00 12,393.18 532.00 60,319.70 2876.00 16,859.75
TNF-a 92.00 137.85 8.00 1173.00 43.50 127.25
VEGF 21.50 25.94 1.90 130.00 10.00 36.00
* Standard deviation. ** 25-percentile. *** 75-percentile
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hypothesized that relapsing depression in the elderly rep-
resents a somewhat different immunological process com-
pared to depression in younger patients, on whom most
studies have been conducted. On the other hand, our
intra-group comparison could be the main explanation
why the depressed patients did not have comparably
higher levels of cytokines, considering that the overall
level of cytokines was high regardless of diagnosis.
One relevant point to consider is that anti-depressants
have exhibited anti-inflammatory properties in both clin-
ical and experimental studies [21, 22]. Accordingly, the
high percentage of antidepressant use in the depression
group (74.6% versus 25.6% in the no depression group)
might have been a factor in terms of lowering the cyto-
kine levels amongst the depressed patients, cancelling
out the association between depression and cytokine
levels.
We did observe a correlation between no depression, a
term denoting patients without significant depression ir-
respective of other clinical features, and several cyto-
kines (FDR-p < 0.0044). Presumably, this correlation is
not explained by the lack of depression per se. Rather, it
is more likely that other factors contribute to increased
cytokines in the no depression group. CVD and demen-
tia are two possible contributing factors, as they are
more prevalent in the no depression group, hence be-
coming predictors in a binary logistic model. Both CVD
and dementia have been linked to increased levels of cy-
tokines [23–26]. Yet, the fact that none of the cytokines
correlated with dementia or CVD, in addition to the ab-
sence of predictive power of any of the cytokines for
both dementia and CVD in binary logistic regression, in-
dicate that other, unrecognized factors also contribute to
the association between no depression and elevated
cytokines.
Finally, it should be taken into account that the total
level of psychiatric morbidity in the no depression group
(e.g. organic mental disorders) was probably just as high,
perhaps higher, than in the depression group, hence di-
luting the potential effect of depression on the cytokine
levels. There might also be a proportion of the no de-
pression patients with dementia that actually was de-
pressed, as it cannot be ruled out that patients with
dementia express depressive symptoms in a way that
is less likely to be recognized by the clinician. Then
again, altered cytokine levels in psychiatric patients
Table 5 Correlation between cytokines and No depression (p-level > 0.01 excluded)
Cytokine Correlation coefficient* p FDR-p** Significant*** Eta2****
IL-2 0.268 0.008 0.0060 No 0.072
bFGF 0.271 0.008 0.0056 No 0.074
IL-1ra 0.271 0.008 0.0052 No 0.074
IL-1b 0.283 0.005 0.0048 No 0.080
IL-5 0.288 0.004 0.0044 Yes 0.083
IL-12 0.289 0.004 0.0040 Yes 0.083
IL-6 0.290 0.004 0.0036 Yes 0.084
TNF-a 0.295 0.004 0.0028 Yes 0.087
IL-7 0.306 0.002 0.0024 Yes 0.093
IL-10 0.321 0.001 0.0020 Yes 0.103
G-CSF 0.322 0.001 0.0016 Yes 0.104
INF-g 0.334 0.001 0.0012 Yes 0.111
IL-4 0.348 0.001 0.0008 Yes 0.121
IL-8 0.349 0.000 0.0004 Yes 0.122
*Spearman Rho; **False detection rate adjusted p-value, q-level 0.01, based on p-values of all 25 cytokines; ***FDR-adjusted p-criterion of 0.0044 ****Effect size.
Based on Mann-Whitney Z-statistics of all 25 cytokines
Table 6 Logistic regression model assessing predictors of patients categorized as no depressiona








95% CIc for OR
Lower - Upper
Dementia (N = 20) 1.422 0.484 8.651 0.003 4.147 1.607–10.700
Cardiovascular disease (N = 18) 1.664 0.515 10.441 0.001 5.279 1.924–14.479
Constant −1.409 0.344 16.745 0.000 0.244
aNagelkerke R Square 0.253, Cox & Snell R Square 0.187
bSE: Standard error
cCI: Confidence interval
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may be a general phenomenon, possibly being primar-
ily dependent on the severity of the disorder, and not
the diagnosis.
When interpreting the result of our study, we need
to be cautious, given the size of the study, and par-
ticularly the size of the subgroups. It should also be
noted that though we chose 0.01 as significance levels
due to multiple comparisons, and calculated FDR-p
for the cytokine statistics, the risk of spurious correla-
tions is still present. On this point, it worth mention-
ing that a Bonferroni correction would have required
a significance threshold of 0.002. Moreover, applying
few exclusion criteria may have provided a study
population that resembled real-life gerontopsychiatric
in-patients, but heightened the risk of confounders
due to the general heterogeneity of the group, i.e. dif-
ferences in age, socioeconomic background, lifestyle
factors etc. Adding to this risk was the possibility of
greater variability in health status, including immuno-
logical functioning, in the elderly compared to youn-
ger adults. Another possible source of cytokine
variability could be that not all blood samples were
fasting (35.7% non-fasting). Though the studies are
somewhat conflicting, most seem to indicate that fast-
ing has a certain anti-inflammatory effect [27–29]. A
correlational analysis between fasting and cytokine
levels in our population demonstrated nevertheless no
correlation. Furthermore, a control group of healthy
elderly would have made a statistical comparison pos-
sible, but at the time, we did not have such data
available. Finally, it should be mentioned that single
imputation of data to remedy NDs (see section Statis-
tical analysis) may confer a risk of distorting the sta-
tistics, in particular when the number of NDs are
high. In our study, the number of NDs are small
(four at the most) and running the statistics without
the NDs did not produce any significant change.
The plasma levels of cytokines observed in this group
of elderly patients were the results of complex immuno-
logical processes, where different cytokines might have
played different roles at different stages. Several inter-
playing factors, such as age, life style factors, somatic
health, genetics, drugs and the psychiatric disorders per
se, may have contributed in these processes. Besides, it
is still unclear how an increased level of cytokines in sys-
temic circulation relates to neuroimmunological pro-
cesses in psychiatric disorders. Adding to the complexity
is the application of various methods of cytokine analysis
and methodological issues [30, 31]. Hence, caution
should be exercised when interpreting data and making
inferences about cytokine profiles and biomarkers in
psychiatry, and perhaps particularly in the elderly popu-
lation. This also begs the question as to what extent
findings in younger adults, with uniform diagnostic
profiles and no comorbidity, have bearings on real-life
elderly patients.
Though the field of old age neuroimmunology has
made great advances in the last decade, there is still a lot
to be learned about the immunology of gerontopsychia-
try. Further studies are needed on gerontopsychiatric pa-
tients in general and gerontopsychiatric patients with
specific disorders, preferably with patients that are phys-
ically healthy. Clinical studies are necessary to gauge the
immunological effects, both cellular and humoral, of
various forms of treatment. As for our patients, the
question is if psychiatric treatment can impact the high,
probably multi-etiological, levels of cytokines. Finally,
genomic and proteomic studies are required to uncover
the immunological underpinnings of psychiatric disor-
ders affecting the elderly, including longitudinal studies
of healthy populations at risk.
Conclusions
There was no significant difference in cytokine levels be-
tween various psychiatric diagnoses in elderly psychiatric
in-patients. However, when patients were allocated to
two groups, depression and no depression, irrespective of
diagnoses and other clinical features, we found higher
levels of certain cytokines in the no depression group
compared to the depression group. This might be due to
a higher frequency of CVD and dementia in the no de-
pression group, as well as other unknown factors.
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